Navigation Links
RainDance Technologies to Dedicate New Headquarters, Manufacturing Facility in Lexington
Date:9/17/2008

- Biomedical technology innovator relocates to Mass. based upon Gov. Deval

Patrick's Life Sciences Initiative -
LEXINGTON, Mass., Sept. 17 /PRNewswire/ --

-- WHO: RainDance Technologies

-- WHAT: Dedication of its new HQ/manufacturing facility

-- WHEN: Friday, Sept. 26, 2008, 3:00 p.m. to 5:00 p.m. EDT

-- WHERE: 44 Hartwell Avenue, Lexington, Mass.

RainDance Technologies, Inc., a provider of innovative droplet-based microfluidic solutions for human health and disease research, will dedicate its new headquarters and commercial and manufacturing operations on Friday, Sept. 26th in Lexington, Mass. at 3:00 p.m.

RainDance's 28,000-square-foot building in Lexington will more than double its former space in Guilford, Conn. RainDance plans to increase its workforce by some 50 percent -- adding new biologists and chemists, mechanical engineers and technicians, software programmers, customer service representatives, and administrative support -- and will employ nearly 100 within the year.

Company officials made the decision to relocate to Massachusetts based on Governor Deval Patrick's Life Sciences Initiative.

RainDance will also announce a collaboration with a major pharmaceutical company to develop a new droplet-based methodology for the drug discovery process.

Agenda:

-- Remarks:

-- Sir Richard Roberts, Nobel Laureate, Physiology/ Medicine, 1993,

RainDance Technologies Scientific Advisory Board

-- Daniel O'Connell, Massachusetts Housing and Economic Development

Secretary

-- Christopher McNary, RainDance Technologies President and Chief

Executive Officer

-- A tour of our new facilities and reception will follow.

RainDance's new RainStorm(TM) droplet-based microfluidic technology has broad use in the prediction and prevention of human disease. The simplicity, speed, and capabilities of the technology will enable researchers to design experiments in ways previously unaffordable or unimaginable. RainStorm technology will find numerous uses in biomedical applications, including genomics research, gene expression analysis, compound screening, and biomarker detection.

RainDance was founded by scientists from Harvard University, the Medical Research Centre in Cambridge, England, and the ESPCI in Paris, and the company's scientific advisers include three Nobel Prize winners plus a pioneer in protein engineering who has been knighted for services to molecular biology.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Steven Becker https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=78145


'/>"/>
SOURCE RainDance Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. RainDance and Scripps to Collaborate on Targeted Sequencing for Wellderly Study
2. RainDance Technologies Appoints Olex Vice President, System Development
3. RainDance Appoints Kelly Chief Operating Officer
4. RainDance Announces Company Relocation and Manufacturing Startup
5. RainDance Appoints Becker Chief Commercial Officer
6. RainDance Technologies Appoints McNary President and CEO
7. Microchip Biotechnologies, Inc. Awarded Contract Under US Army Commercialization Pilot Program
8. Tethys Bioscience Announces Acquisition of Lipomics Technologies
9. Althea Technologies Secures $12 M Credit Line to Continue Facility Growth and Expansion
10. Epeius Biotechnologies Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal
11. Neptune Technologies decided not to re-price options
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2017)... ... May 20, 2017 , ... ... the lengthy trial and error process by finding the right antidepressant faster. ... strengthen the doctor-patient relationship through a personalized approach to treatment. , ...
(Date:5/18/2017)... (PRWEB) , ... May 18, 2017 , ... ... procedure on April 28, 2017 at the Prince Of Wales Private Hospital. The ... disc at level C6-C7. The patient failed conservative treatments prior to undergoing surgery. ...
(Date:5/18/2017)... , ... May 17, 2017 , ... NDA Partners Chairman ... and former CEO of Eurofins Advantar Laboratories and President of Pharmaceutical Development Business Unit ... his position at Eurofins and Cardinal Health, he was former Chief Operating Officer at ...
(Date:5/18/2017)... ... May 17, 2017 , ... USDM Life Sciences ... the life sciences and healthcare industries, is honored that Jay Crowley ... conference in Brussels, Belgium. , Crowley played a crucial role in the development ...
Breaking Biology Technology:
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/30/2017)... 30, 2017 Trends, opportunities and forecast in ... by technology (fingerprint, AFIS, iris recognition, facial recognition, hand ... by end use industry (government and law enforcement, commercial ... banking, and others), and by region ( North ... Asia Pacific , and the Rest of ...
(Date:3/27/2017)... 2017  Catholic Health Services (CHS) has been ... (HIMSS) Analytics for achieving Stage 6 on the ... In addition, CHS previously earned a place in ... electronic medical record (EMR). "HIMSS Analytics ... EMR usage in an outpatient setting.  This recognition ...
Breaking Biology News(10 mins):